Skip to content

Study · Randomized controlled trial · n = 1,645 · 2017

5 results

The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study.

McCloskey EV, Johansson H, Oden A, Harvey NC, Jiang H, Modin S, Fitzpatrick L, Kanis JA

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research26 Jun 2017Cited by 39 (Europe PMC)

PMID28474780 (opens in a new tab)PMCIDPMC5553106 (opens in a new tab)DOI10.1002/jbmr.3163 (opens in a new tab)PepBankPUB-28474780
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, abaloparatide reduced major osteoporotic fractures compared with placebo.

    In plain wordsIn postmenopausal women, abaloparatide reduced major osteoporotic fractures compared with placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseMajor osteoporotic fractures
    Study

    n = 1,645

    Comparator
    placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 mcg daily · subcutaneous · 18 monthsAs given in this study (human).

    Measurements

    Risk reduction
    69%
    major osteoporotic fracture

    Source sentences

    Summary
    Treatment with abaloparatide-SC was associated with a 69% (95% confidence interval [CI] 38-85%) decrease in major osteoporotic fracture (MOF) and a 43% (95% CI 9-64%) decrease in any clinical fracture compared with placebo.
    1 context sentence
    Summary · context
    A total of 821 women randomized to placebo and 824 women to abaloparatide-SC, mean age 69 years in both groups, were followed for up to 2 years.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, abaloparatide reduced any clinical fracture compared with placebo.

    In plain wordsIn postmenopausal women, abaloparatide reduced clinical fractures compared with placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseAny clinical fracture
    Study

    n = 1,645

    Comparator
    placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 mcg daily · subcutaneous · 18 monthsAs given in this study (human).

    Measurements

    Risk reduction
    43%
    any clinical fracture

    Source sentences

    Summary
    Treatment with abaloparatide-SC was associated with a 69% (95% confidence interval [CI] 38-85%) decrease in major osteoporotic fracture (MOF) and a 43% (95% CI 9-64%) decrease in any clinical fracture compared with placebo.
    1 context sentence
    Summary · context
    A total of 821 women randomized to placebo and 824 women to abaloparatide-SC, mean age 69 years in both groups, were followed for up to 2 years.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, abaloparatide fracture hazard ratios versus placebo tended to decrease as baseline fracture probability increased.

    In plain wordsIn postmenopausal women, abaloparatide fracture hazard ratios versus placebo tended to decrease as baseline risk increased.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    DecreaseFracture hazard trend with baseline probability
    Study

    n = 1,645

    Comparator
    placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 mcg daily · subcutaneous · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    For all outcomes, hazard ratios tended to decrease (ie, greater efficacy) with increasing fracture probability.
    1 context sentence
    Summary · context
    A total of 821 women randomized to placebo and 824 women to abaloparatide-SC, mean age 69 years in both groups, were followed for up to 2 years.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, baseline fracture probability did not significantly interact with abaloparatide efficacy against any fracture versus placebo.

    In plain wordsIn postmenopausal women, baseline risk did not significantly change abaloparatide efficacy against any fracture versus placebo.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeBaseline-risk interaction with any fracture efficacy
    Study

    n = 1,645

    Comparator
    placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 mcg daily · subcutaneous · 18 monthsAs given in this study (human).

    Measurements

    Interaction P value
    0.11 P
    any fracture

    Source sentences

    Summary
    Whereas the interaction approached significance for the outcome of any fracture (p = 0.11), there was no statistically significant interaction for any of the fracture outcomes.
    1 context sentence
    Summary · context
    A total of 821 women randomized to placebo and 824 women to abaloparatide-SC, mean age 69 years in both groups, were followed for up to 2 years.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, no fracture outcome showed a statistically significant interaction between baseline probability and abaloparatide efficacy versus placebo.

    In plain wordsIn postmenopausal women, baseline risk did not significantly change abaloparatide efficacy versus placebo across fracture outcomes.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    No significant changeBaseline-risk interaction across fracture outcomes
    Study

    n = 1,645

    Comparator
    placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    80 mcg daily · subcutaneous · 18 monthsAs given in this study (human).

    Source sentences

    Summary
    Whereas the interaction approached significance for the outcome of any fracture (p = 0.11), there was no statistically significant interaction for any of the fracture outcomes.
    1 context sentence
    Summary · context
    A total of 821 women randomized to placebo and 824 women to abaloparatide-SC, mean age 69 years in both groups, were followed for up to 2 years.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.